Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)

References

• Leila K, Wang XH, Christopher JS, et al. Bruton’s tyrosine kinase is a potential therapeutic target in prostate cancer. Cancer Biol Ther. 2016;11:1604–1615.
   Google Scholar
• Brahmam P, Anil KA, Sandip M, et al. Discovery of pyrazolopyrimidine derivatives as novel dual inhibitors of BTK and PI3Kδ. ACS Med Chem Lett. 2016;7:1161−1166.
   PubMed Web of Science ®Google Scholar
• Liu J, Deodial G, Arto K, et al. Discovery of 8‑amino-imidazo[1,5‑a]pyrazines as reversible BTK inhibitors for the treatment of rheumatoid arthritis. ACS Med Chem Lett. 2016;7:198−203.
   PubMed Web of Science ®Google Scholar
• Wang XJ, James B, Peter B, et al. Discovery of potent and selective tricyclic inhibitors of bruton’s tyrosine kinase with improved druglike properties. ACS Med Chem Lett. 2017;8:608−613.
   PubMed Web of Science ®Google Scholar
• Liang CY, Tian DN, Ren XD, et al. The development of Bruton’s Tyrosine Kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Eur J Med Chem. 2018;151:315–326.
   PubMed Web of Science ®Google Scholar
• Ge Y, Jin Y, Wang CY, et al. Discovery of novel bruton’s tyrosine kinase (BTK) inhibitors bearing a N,9-diphenyl‑9H‑purin-2-amine scaffold. ACS Med Chem Lett. 2016;7:1050−1055.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473–4479.
   PubMed Web of Science ®Google Scholar
• Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobu- linaemia is a member of the src family of protein-tyrosine kinases. Nature. 1993;361:226−233.
   PubMed Web of Science ®Google Scholar
• Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem. 2007;2:58−61.
   PubMed Web of Science ®Google Scholar
• Anella Y, Sarah AM, Rick AS, et al. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors. Journal.Pone. 2017;12(2):1–21.
   Google Scholar
• Simar PS, Floris D, Rudi WH. Role of bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57.
   PubMed Web of Science ®Google Scholar
• Zuo YY, Pan ZY. Small-molecule inhibitors of bruton’s tyrosine kinase. Top Med Chem. 2017;59:7915-7935.
   PubMedGoogle Scholar
• Wendy B, Young JB, Peter B, et al. Potent and selective Bruton’s tyrosine kinase inhibitors: discovery of GDC-0834. Bioorg Med Chem Lett. 2015;25:1333–1337.
   PubMedGoogle Scholar
• Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in waldenström macroglobulinemia. Blood. 2013 Jul 15;88(7):1222–1232.
   Google Scholar
• Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström’s Macroglobulinemia. N Engl J Med. 2015 Aug 6;373(6):584–586.
   PubMed Web of Science ®Google Scholar
• Phelan JD, Young RM, Webster DE, et al. A multiprotein supercomplex controlling oncogenic signaling in lymphoma. Nature. 2018;560(7718):387–391. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies, Nat. Rev Cancer. 2014;14:219–232.
   PubMed Web of Science ®Google Scholar
• Advani R, Buggy JJ, Sharman JP, et al. The Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Clin Oncol. 2013;31:88–94.
   Web of Science ®Google Scholar
• Yang G, Buhrlage SJ, Tan L, et al. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 May 3;127(25):3237–3252.
   PubMed Web of Science ®Google Scholar
• Barf T, Covey T, Izumi R, et al. Acalabrutinib (ACP-196): A covalent bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. Bioorg J Pharmacol Exp Ther. 2017;363:240–252.
   PubMed Web of Science ®Google Scholar
• Brown JR, Harb WA, Hill BT, et al. Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory Chronic Lymphocytic Leukemia. Haematologica. 2016; 101(7): e295-e298.
   Google Scholar
• Kim YY, Park KT, Jang SY, et al. HM71224, a selective Bruton’s tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017;19:211.
   PubMed Web of Science ®Google Scholar
• Gillooly KM, Pulicicchio C, Pattoli MA, et al. Bruton’s tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. PLoS One. 2017;12:e0181782.
   PubMed Web of Science ®Google Scholar
• Wu JJ. Zhang MZ and Liu DL. Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. Oncotarget. 2017;8:7201–7207.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang L, Yuan Y, et al. Identification of metabolites of evobrutinib in rat and human hepatocytes by using ultra-high performance liquid chromatography coupled with diode array detector and Q exactive orbitrap tandem mass spectrometry. Drug Test Anal. 2019;11:129–139.
   PubMed Web of Science ®Google Scholar
• Reiff SD, Muhowski EM, Guinn D, et al. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. Blood. 2018;132:1039–1049.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Burger JA. Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018;27:31–42.
   PubMed Web of Science ®Google Scholar
• Smith PF, Krishnarajah J, Nunn PA, et al. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers. Br J Clin Pharmacol. 2017;83(11):2367–2376.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/results?cond=&term=BTK+inhibitor&cntry=&state=&city=&dist=
   Google Scholar
• Zhao X, Xin M, Huang W, et al. Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton’s tyrosine kinase inhibitors. Bioorg Med Chem. 2015;23:348–364.
   PubMedGoogle Scholar
• Xin M, Zhao X, Huang W, et al. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridine-4-amines as potent reversible Bruton’s Tyrosine Kinase (BTK) inhibitors. Bioorg Med Chem. 2015;23:6250–6257.
   PubMedGoogle Scholar
• Lou Y, Han X, Kuglstatter A, et al. Structure-based drug design of RN486, a potent and selective Bruton’s Tyrosine Kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis. J Med Chem. 2015;58:512–516.
   PubMed Web of Science ®Google Scholar
• Zhao X, Xin M, Wang Y, et al. Discovery of thieno[3,2-c]pyridine-4-amines as novel Bruton’s Tyrosine Kinase (BTK) inhibitors. Bioorg Med Chem. 2015;23:6059–6068.
   PubMedGoogle Scholar
• Wang X, Wong J, Sevinsky CJ, et al. Bruton’s tyrosine kinase inhibitors prevent therapeutic escape in breast cancer cells. Mol Cancer Ther. 2016;15:2198–2208.
   PubMed Web of Science ®Google Scholar
• Young WB, Barbosa J, Blomgren P, et al. Discovery of highly potent and selective Bruton’s tyrosine kinase inhibitors: pyridazinone analogs with improved metabolic stability. Bioorg Med Chem Lett. 2016;26:575–579.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol. 2013;3:107.
   PubMedGoogle Scholar
• Dae Woong Pharma. Novel 4-aminopyrazolo[3,4-d]Pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same. WO2018009017; 2018.
   Google Scholar
• Redx Pharma Plc. Pyrazolopyrimidine derivatives as Btk inhibitors for the treatment of cancer. WO2017046604; 2017.
   Google Scholar
• Pharmacyclics Llc. Inhibitors of bruton’s tyrosine kinase. WO2016019233; 2016.
   Google Scholar
• Zhejiang Dtrm Biopharma Co. Ltd. Polyfluorinated compounds acting as bruton tyrosine kinase iInhibitors. US20160200730; 2016.
   Google Scholar
• Redx Pharma Plc. Pyrazolo-pyrimidines as inhibitors of Btk. WO2015140566; 2015.
   Google Scholar
• Cadila Healthcare Ltd. Heterocyclic Compounds. WO2015132799; 2015.
   Google Scholar
• Pharmacyclics Inc. Inhibitors of bruton’s tyrosine kinase. WO2015048689;2015.
   Google Scholar
• Principia Biopharma Inc. Tyrosine kinase inhibitors. WO2012158764; 2012.
   Google Scholar
• Redx Pharma Ltd. Pyrazolopyrimidine derivatives useful as inhibitors of bruton’s tyrosine kinase. WO2014188173; 2014.
   Google Scholar
• Principia Biopharma Inc. Pyrazolopyrimidine Compounds as kinase inhibitors. WO2014039899; 2014.
   Google Scholar
• Boehringer Ingelheim Int. Heteroaromatic compounds as Btk inhibitors. US20140275014; 2014.
   Google Scholar
• Merck Sharp & Dohme. Btk inhibitors. WO2014116504; 2014.
   Google Scholar
• Taiho Pharmaceutical Co Ltd. Novel fused pyrimidine compound or salt thereof. WO2015022926; 2015.
   Google Scholar
• Glaxosmithkline Llc. Chemical Compounds. WO2011119663; 2011.
   Google Scholar
• Shanghai Dude Medical Tech Co Ltd. Heteroaryl compound having pharmaceutical activity. WO2018233655; 2018.
   Google Scholar
• Hangzhou Hertz Pharmaceutical Co Ltd. Selective bruton’s tyrosine kinase inhibitor and use thereof. WO2018090792; 2018.
   Google Scholar
• Pharmascience Inc. Heterocyclic tec-family kinase inhibitors. WO2017041180; 2017.
   Google Scholar
• Zhejiang Yukon Pharma Co Ltd. Pyrazolopyrimidine derivative as BTK inhibitor and preparation method and pharmaceutical composition thereof. WO2017198049; 2017.
   Google Scholar
• Guangdong Dongyangguang Pharmaceutical Co Ltd. Preparation of 4-amino-3-(alkylethynyl)-1H-pyrazolo[3,4-d]pyrimidine derivatives useful as BTK inhibitors. CN201710309938; 2017.
   Google Scholar
• Ono Pharmaceutical Co, Shingo Y, Toshio Y. Purinone derivative. WO2011152351; 2011.
   Google Scholar
• Pharmacyclics Inc. Purinone compounds as kinase inhibitors. WO2015002894; 2015.
   Google Scholar
• Sunnylife Pharma Inc, Shanghai Inst Materia Medica Cas. Bruton’s tyrosine kinase inhibitors. WO2017066014; 2017.
   Google Scholar
• Gilead Sciences Inc, Ono Pharmaceutical Co. Inhibitors of bruton’s tyrosine kinase. WO2018156901; 2018.
   Google Scholar
• Sun Pharma Advanced Res Company Limited. Novel hydrazide containing compounds as BTK inhibitors. WO2018002958; 2018.
   Google Scholar
• Pharmacyclics Inc. Pyrrolopyrimidine compounds as kinase inhibitors. WO2014078578; 2014.
   Google Scholar
• Shanghai Inst Materia Medica Cas. Pyrimido[5,4-b]Indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof. WO2018095398; 2018.
   Google Scholar
• Univ China Pharma. 4-aminopyrimidine compound, and preparation method therefor and application thereof. WO2018196757; 2018.
   Google Scholar
• Hangzhou Huadong Medicine Group Pharmaceutical Res Institute Co Ltd. Imidazopyridinamine phenyl derivative and use thereof. WO2018001331; 2018.
   Google Scholar
• Acerta Pharma Bv. Imidazopyrazine inhibitors of bruton’s tyrosine kinase. WO2017077507; 2017.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. WO2016196418; 2016.
   Google Scholar
• Merck Sharp & Dohme. Benzamide imidazopyrazine BTK inhibitors. WO2016109223; 2016.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. WO2016109221; 2016.
   Google Scholar
• Merck Sharp & Dohme. Biarylether imidazopyrazine BTK inhibitors. WO2016109219; 2016.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. WO2016109215; 2016.
   Google Scholar
• Merck Sharp & Dohme. Imidazopyrazine analogs with 3-tertiary carbon substitutions as BTK inhibitors. WO2016109220; 2016.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. WO2016109216; 2016.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. WO2016109217; 2016.
   Google Scholar
• Merck Sharp & Dohme. Tertiary alcohol imidazopyrazine BTK inhibitors. WO2016109222; 2016.
   Google Scholar
• Kim RM, Liu J, Gao XL, et al. BTK inhibitors. US20140206681; 2014.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. WO2013010380; 2013.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. US20150353565; 2015.
   Google Scholar
• Chengdu Shibeikang Biomedical Technology Co Ltd. Pyrrolidine bruton’s tyrosine kinase inhibitor and its application. CN201810076251; 2018.
   Google Scholar
• Chengdu Bite Pharmaceutical Co Ltd. Bruton’s tyrosine kinase inhibitor, its preparation method and application in preparation of drugs for treating autoimmune disease, inflammatory disease and cancer. CN201810002152; 2018.
   Google Scholar
• Dongguan Zhenxing Beite Medicine Tech Co Ltd. Imidazopyrazine compound, preparation method therefor and use thereof. WO2018130213; 2018.
   Google Scholar
• Chengdu Brilliant Pharmaceutical Co Ltd, Chengdu Highbred Pharmaceutical Co Ltd. Compound used as bruton’s tyrosine kinase inhibitor and preparation method and application thereof. WO2018133151; 2018.
   Google Scholar
• Suzhou Baijibugong Pharmaceutical Tech Co Ltd. Bruton’s tyrosine kinase inhibitors. WO2018175512; 2018.
   Google Scholar
• Neupharma Inc. Certain chemical entities, compositions, and methods. WO2018035061; 2018.
   Google Scholar
• Merck Sharp & Dohme. Btk inhibitors. WO2015095099; 2015.
   Google Scholar
• Merck Sharp & Dohme. BTK inhibitors. WO2015095102; 2015.
   Google Scholar
• Principia Biopharma Inc. Tyrosine kinase inhibitors. WO2016210165; 2016.
   Google Scholar
• Locus Pharmaceuticals Inc. Pyrrolotriazine compounds. WO2010126960; 2010.
   Google Scholar
• Hubei Bio Pharmaceutical Ind Technological Inst Inc, Humanwell Healthcare Group Co Ltd. BTK inhibitor. WO2016112637; 2016.
   Google Scholar
• Joint Stock Company Biocad. Inhibitors of bruton’s tyrosine kinase. WO2018092047; 2018.
   Google Scholar
• Sunnylife Pharma Inc, Shanghai Inst Materia Medica Cas. Bruton’s tyrosine kinase inhibitors. WO2017127371; 2017.
   Google Scholar
• Shanghai Fochon Pharmaceutical Co Ltd, Chongqing Fochon Pharmaceutical Co Ltd. Substituted pyrrolo [2, 3-d] pyridazin-4-ones and pyrazolo [3, 4-d] pyridazin-4-ones as protein kinase inhibitors. WO2017219955; 2017.
   Google Scholar
• Gmbh MP, Qiu H, Caldwell RD, et al. Pyrimidine derivatives as BTK inhibitors and uses thereof. WO2017007987; 2017.
   Google Scholar
• Acea Biosciences Inc. Heterocyclic compounds and uses thereof. WO2015006754; 2015.
   Google Scholar
• Dana Farber Cancer Inst Inc. Kinase inhibitors for the treatment of disease. WO2015006492; 2015.
   Google Scholar
• Celgene Avilomics Res Inc. Heteroaryl compounds and uses thereof. WO2014100748; 2014.
   Google Scholar
• Kbp Biosciences Co Ltd. Nitrogen-containing heteroaromatic ring derivative as tyrosine kinase inhibitor. WO2014040555; 2014.
   Google Scholar
• Lupin Ltd. Substituted pyrimidine compounds as BTK inhibitors. WO2015170266; 2015.
   Google Scholar
• Merck Patent G, Hodous BL, Liu-Bujalski L, et al. Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity. WO2012170976; 2012
   Google Scholar
• Novartis A, Briard E, Auberson Y, et al. Labeled amino pyrimidine derivatives. WO2016079669; 2016.
   Google Scholar
• The First Affiliated Hospital of Dalian Medical University. Pyrimidine compound, composition and its application in treatment of lymphoma leukemia. CN201810299255; 2018.
   Google Scholar
• Zhengda Tianqing Pharmaceutical Group Co Ltd. Bruton’s tyrosine kinase (BTK) inhibitor for preparing drugs for preventing or treating BTK-mediated diseases. CN201810020706; 2018.
   Google Scholar
• Univ Peking Shenzhen Grad Scho. Kinase inhibitor and method for treating related diseases. WO2014169710; 2014.
   Google Scholar
• Kbp Biosciences Co Ltd. Bicyclic compound functioning as tyrosine kinase inhibitor. WO2014089913; 2014.
   Google Scholar
• Redx Pharma Limited (Incorporated in the United Kingdom). Triazine derivatives and their use as BTK inhibitors. GB2516303; 2015.
   Google Scholar
• Univ East China Science & Tech, Shanghai Inst Materia Medica Cas. Heterocyclic compound as BTK inhibitor and application thereof. WO2018192532; 2018.
   Google Scholar
• East China University of Science and Technology. Preparation of the heterocyclic compound as BTK inhibitor and their medical application. CN201710258020; 2017.
   Google Scholar
• Univ Peking Shenzhen Graduate School, Beijing Reciproca Pharmaceuticals Co Ltd. Novel inhibitors and probes for kinases and uses thereof. WO2017063103; 2017.
   Google Scholar
• Acea Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases. WO2014025486; 2014.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. WO2014135473; 2014.
   Google Scholar
• CGI Pharmaceuticals Inc, Genentech Inc. Certain substituted amides, method of making, and method of use thereof. WO2010068810; 2010.
   Google Scholar
• Beijing Hanmei Pharmaceutical Co Ltd. Compounds that inhibit BTK and/or JAK3 kinase activity. CN201410478741; 2014.
   Google Scholar
• Humanwell Healthcare Group Co Ltd. Compound and preparation method and use thereof. WO2015184661; 2015.
   Google Scholar
• Zhang DW Substituted quinolines as bruton’s tyrosine kinases inhibitors. WO2013152135; 2013.
   Google Scholar
• Korea Res Inst Chemical Tech. Pyrazolopyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating cancer, autoimmune disease and brain disease containing the same as an active ingredient. WO2018208132; 2018.
   Google Scholar
• Dae Woong Pharma. Pyrazolopyrimidine derivatives as kinase inhibitor. WO2018004306; 2018.
   Google Scholar
• Dae Woong Pharma. Pyrrolotriazine derivatives as kinase inhibitor. WO2018169373; 2018.
   Google Scholar
• Lupin Ltd. Substituted purine compounds as BTK inhibitors. WO2015151006; 2015.
   Google Scholar
• Arqule Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof. WO2018039310; 2018.
   Google Scholar
• Dae Woong Pharma. Novel pyrrolopyrimidine derivatives and pharmaceutical composition comprising the same. WO2018088780; 2018.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. WO2014064131; 2014.
   Google Scholar
• Redx Pharma Limited (Incorporated in the United Kingdom). Fused-ring heterocyclic compounds and their use as BTK inhibitors. GB2515785; 2015.
   Google Scholar
• Gmbh MP. Pyridines, pyrimidines, and pyrazines, as BTK inhibitors and uses thereof. WO2015017502; 2015.
   Google Scholar
• Pharmacyclics Llc, Schrödinger Llc, Pharmacyclics Inc. Inhibitors of bruton’s tyrosine kinase. US20160002241; 2016.
   Google Scholar
• Shanghai Aeon Biotech Co Ltd. Heterocycle compounds and uses thereof. WO2017096100; 2017.
   Google Scholar
• Merck patent GMBH. 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof. WO2018035080; 2018.
   Google Scholar
• Biogen Ma Inc. Benzoazepine analogs as inhibiting agents for bruton’s tyrosine kinase. WO2018191577; 2018.
   Google Scholar
• Pharmacyclics Llc. Pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of bruton’s tyrosine kinase. US20180194762; 2018.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. WO2014161799; 2014.
   Google Scholar
• Hanmi Pharm Ind Co Ltd. Novel imidazopyridine derivatives as a tyrosine kinase inhibitor. WO2013100631; 2013.
   Google Scholar
• The National Institutes of Pharmaceutical Res and Development Nip. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. WO2018145525; 2018.
   Google Scholar
• Shanghai Institute of Materia Medica. Thieno[3,2-d] pyrimidines as BTK inhibitor and preparation method. CN201710244485; 2017.
   Google Scholar
• Janssen Pharmaceutica Nv, Nidhi A. Inhibitors of bruton’s tyrosine kinase and methods of their use. WO2017100662; 2017.
   Google Scholar
• Janssen Pharmaceutica Nv, Min C. Inhibitors of bruton’s tyrosine kinase and methods of their use. WO2018103058; 2018.
   Google Scholar
• Arqule Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof. US9630968; 2017.
   Google Scholar
• Genentech Inc. 8-fluorophthalazin-1 (2h) - One compounds as inhibitors of BTK activity. WO2013067264; 2013.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. WO2014135470; 2014.
   Google Scholar
• Chen Y Inhibitors of bruton’s tyrosine kinase. WO2015050703; 2015.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. WO2013083666; 2013.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. WO2012156334; 2012.
   Google Scholar
• Merck Sharp & Dohme. Indazole and azaindazole BTK inhibitors. WO2016164285; 2016.
   Google Scholar
• Carna Biosciences Inc. Novel oxoisoquinoline derivative. WO2018097234; 2018.
   Google Scholar
• Hoffmann LR Novel phenylimidazopyrazines. WO2010006970; 2010.
   Google Scholar
• Jiangsu Simcere Pharmaceutical. Bruton’s tyrosine kinase inhibitor. WO2014187262; 2014.
   Google Scholar
• Hoffmann LR Novel phenyl-imidazopyridines and pyridazines. WO2010006947; 2010.
   Google Scholar
• Advinus Therapeutics Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof. WO2013157022; 2013.
   Google Scholar
• Carna Biosciences Inc. Novel 1,2,4-triazine derivative. WO2013161848; 2013.
   Google Scholar
• Impetis Biosciences Limited, Advinus Therapeutics Limited Applicant: Advinus Therapeutics Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof. US20150064196; 2015.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. US20150376166; 2015.
   Google Scholar
• Hoffmann LR Inhibitors of bruton’s tyrosine kinase. WO2014076104; 2014.
   Google Scholar
• Gilead Connecticut Inc. Pyridone and aza-pyridone compounds and methods of use. WO2011140488; 2011.
   Google Scholar
• Hefei Inst Physical Sci Cas. Novel irreversible bruton’s tyrosine kinase inhibitor. WO2017133341; 2017.
   Google Scholar
• Nanjing Vocational College of Science and Technology. Preparation of pyrazolo[4,3-c]pyridine-4(5)-one bruton kinase inhibitor. CN201710208174; 2017.
   Google Scholar
• Boehringer Ingelheim Int. Isoquinolones as BTK inhibitors. WO2017123695; 2017.
   Google Scholar
• Boehringer Ingelheim Int. Bipyrazolyl derivatives useful for the treatment of autoimmune diseases. WO2017106429; 2017.
   Google Scholar
• Boehringer Ingelheim Int. Pyrazole compounds as BTK inhibitors. WO2015116485; 2015.
   Google Scholar
• Beigene Ltd. Protein kinase inhibitors and uses thereof. US20150005277; 2015.
   Google Scholar
• Pfizer. Bruton’s tyrosine kinase inhibitors. WO2014068527; 2014.
   Google Scholar
• Boehringer Ingelheim Int. Heteroaromatic compounds as BTK inhibitors. US20140265012; 2014.
   Google Scholar
• Redx Pharma Plc. Compounds useful as kinase inhibitors. WO2017103611; 2017.
   Google Scholar
• Beigene Ltd. Fused heterocyclic compounds as protein kinase inhibitors. WO2014173289; 2014.
   Google Scholar
• Redx Pharma Plc. Compounds useful as kinase inhibitors. WO2017198050; 2017.
   Google Scholar
• Beigene Ltd, Zhiwei W, Yunhang G. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof. WO2018033853; 2018.
   Google Scholar
• La Roche H, Chugai Pharmaceutical Co Ltd. Inhibitors of bruton’s tyrosine kinase. WO2015086636; 2015.
   Google Scholar
• La Roche H, Chugai Pharmaceutical Co Ltd. Inhibitors of bruton’s tyrosine kinase. WO2015086635; 2015.
   Google Scholar
• La Roche H, Chugai Pharmaceutical Co Ltd. Inhibitors of bruton’s tyrosine kinase. WO2015086642; 2015.
   Google Scholar
• Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds. US20140275023; 2014.
   Google Scholar
• Merck Sharp & Dohme. Indazole and azaindazole Btk inhibitors. WO2016164284; 2016.
   Google Scholar
• Squibb Bristol Myers Co. Tricyclic atropisomer compounds. WO2016065222; 2016.
   Google Scholar
• Squibb Bristol Myers Co. Carbazole carboxamide compounds useful as kinase inhibitors. WO2014210087; 2014.
   Google Scholar
• Ningbo Wenda Pharmaceutical Technology Co Ltd. Bruton tyrosine kinase inhibitor. CN201510175762; 2015.
   Google Scholar
• Bristol-myers Squibb Company. Substituted tetrahydrocarbazole and carbazole carboxamide compounds. US20140378475; 2014.
   Google Scholar
• Beigene Ltd. Fused heterocyclic compounds as protein kinase inhibitors. WO2014173289; 2014.
   Google Scholar
• Crystalgenomics Inc. 2,3-dihydro-isoindole-1-on Derivative as BTK kinase suppressant, and pharmaceutical composition including same. WO2014104757; 2014.
   Google Scholar
• Takeda Pharmaceutical. Cinnoline derivatives as BTK inhibitors. WO2013148603; 2013.
   Google Scholar
• Inst Químic De Sarriá Cets Fundació Privada, Hospital Clínic De Barcelona, Fundació Clinic Per A La Recerca Biomèdica Fcrb, Inst Investigacions Biomèdiques August Pi I Sunyer. 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]Pyrimidin-7(8h)-one derivatives, synthesis and uses thereof. WO2014198960; 2014.
   Google Scholar
• Biogen Idec Inc, Sunesis Pharmaceuticals Inc. Pyrimidinyl tyrosine kinase inhibitors. WO2013185084; 2013.
   Google Scholar
• Xin MH. Hedgehog inhibitors: a patent review (2013 - present). Expert Opin Ther Pat. 2015;25:549–565.
   PubMed Web of Science ®Google Scholar
• Adam RJ, Pawan BK, Arna K, et al. Battling BTK mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations. ACS Chem Biol. 2016;11:2897−2907.
   PubMed Web of Science ®Google Scholar
• Liu L, Shi B, Wang X, et al. Strategies to overcome resistance mutations of Bruton’s tyrosine kinase inhibitor ibrutinib. Future Med Chem. 2018;10:343–356.
   PubMed Web of Science ®Google Scholar